Pharma-Bio Serv, Inc. (PBSV) stock
PBSVOTCServices-Management Consulting ServicesFiscal year ends October 31
$0.48+0.08 (+20.00%)
Close on Oct 19, 2026Market cap $11.00MP/E 48.0Yield –
Pharma-Bio Serv profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Pharma-Bio Serv's profit margin for the twelve months ending Jul 31, 2026 was 2.7%. For fiscal 2025 it was -1.1%, against -8.2% the year before. The highest annual figure on record is 16.0% in fiscal 2012.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Oct 31, 2025 | -1.1% | +7.1 |
| FY2024 | Oct 31, 2024 | -8.2% | −15.9 |
| FY2023 | Oct 31, 2023 | 7.7% | +2.5 |
| FY2022 | Oct 31, 2022 | 5.2% | +15.6 |
| FY2021 | Oct 31, 2021 | -10.4% | −19.9 |
| FY2020 | Oct 31, 2020 | 9.5% | −1.2 |
| FY2019 | Oct 31, 2019 | 10.7% | +3.5 |
| FY2018 | Oct 31, 2018 | 7.2% | +17.8 |
| FY2017 | Oct 31, 2017 | -10.6% | −9.3 |
| FY2016 | Oct 31, 2016 | -1.3% | −8.3 |
| FY2015 | Oct 31, 2015 | 6.9% | −1.8 |
| FY2014 | Oct 31, 2014 | 8.8% | −6.1 |
| FY2013 | Oct 31, 2013 | 14.8% | −1.2 |
| FY2012 | Oct 31, 2012 | 16.0% | +0.2 |
| FY2011 | Oct 31, 2011 | 15.8% | +12.6 |
| FY2010 | Oct 31, 2010 | 3.3% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026CQ2 2026 | Jul 31, 2026 | -0.6% | +9.8 |
| Q2 FY2026CQ1 2026 | Apr 30, 2026 | 8.6% | +4.7 |
| Q1 FY2026CQ4 2025 | Jan 31, 2026 | 1.4% | +1.1 |
| Q4 FY2025CQ3 2025 | Oct 31, 2025 | -0.0% | −0.7 |
| Q3 FY2025CQ2 2025 | Jul 31, 2025 | -10.4% | +2.4 |
| Q2 FY2025CQ1 2025 | Apr 30, 2025 | 3.9% | +12.9 |
| Q1 FY2025CQ4 2024 | Jan 31, 2025 | 0.3% | +11.7 |
| Q4 FY2024CQ3 2024 | Oct 31, 2024 | 0.7% | +2.0 |
| Q3 FY2024CQ2 2024 | Jul 31, 2024 | -12.8% | −24.3 |
| Q2 FY2024CQ1 2024 | Apr 30, 2024 | -9.0% | −17.9 |
| Q1 FY2024CQ4 2023 | Jan 31, 2024 | -11.4% | −21.4 |
| Q4 FY2023CQ3 2023 | Oct 31, 2023 | -1.3% | −7.0 |
| Q3 FY2023CQ2 2023 | Jul 31, 2023 | 11.5% | +98.6 |
| Q2 FY2023CQ1 2023 | Apr 30, 2023 | 8.9% | −36.7 |
| Q1 FY2023CQ4 2022 | Jan 31, 2023 | 10.1% | +5.3 |
| Q1 FY2022CQ4 2021 | Jul 31, 2022 | 5.6% | −0.3 |
| Q4 FY2021CQ3 2021 | Oct 31, 2021 | -87.1% | −89.9 |
| Q3 FY2021CQ2 2021 | Jul 31, 2021 | 45.6% | +34.6 |
| Q2 FY2021CQ1 2021 | Apr 30, 2021 | 4.8% | −7.4 |
| Q1 FY2021CQ4 2020 | Jan 31, 2021 | 6.0% | −5.4 |
| Q4 FY2020CQ3 2020 | Oct 31, 2020 | 2.9% | −7.0 |
| Q3 FY2020CQ2 2020 | Jul 31, 2020 | 11.0% | +2.3 |
| Q2 FY2020CQ1 2020 | Apr 30, 2020 | 12.2% | −1.6 |
| Q1 FY2020CQ4 2019 | Jan 31, 2020 | 11.4% | +1.1 |
| Q4 FY2019CQ3 2019 | Oct 31, 2019 | 9.9% | −49.0 |
| Q3 FY2019CQ2 2019 | Jul 31, 2019 | 8.7% | −7.1 |
| Q2 FY2019CQ1 2019 | Apr 30, 2019 | 13.7% | +17.1 |
| Q1 FY2019CQ4 2018 | Jan 31, 2019 | 10.3% | +81.8 |
| Q4 FY2018CQ3 2018 | Oct 31, 2018 | 58.9% | +99.4 |
| Q3 FY2018CQ2 2018 | Jul 31, 2018 | 15.8% | +19.9 |
| Q2 FY2018CQ1 2018 | Apr 30, 2018 | -3.4% | +4.8 |
| Q1 FY2018CQ4 2017 | Jan 31, 2018 | -71.5% | −62.0 |
| Q4 FY2017CQ3 2017 | Oct 31, 2017 | -40.5% | −29.5 |
| Q3 FY2017CQ2 2017 | Jul 31, 2017 | -4.1% | −1.4 |
| Q2 FY2017CQ1 2017 | Apr 30, 2017 | -8.2% | – |
| Q1 FY2017CQ4 2016 | Jan 31, 2017 | -9.4% | – |
| Q4 FY2016CQ3 2016 | Oct 31, 2016 | -11.1% | – |
| Q3 FY2016CQ2 2016 | Jul 31, 2016 | -2.7% | – |
See a number that looks wrong?